A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation - Wikidata - awgldk - TriplyDB

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation

http://www.wikidata.org/entity/Q34904065

about

Recent progress in pancreatic cancer Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer Molecular therapeutics in pancreas cancer From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells Viro-immune therapy: A new strategy for treatment of pancreatic cancer Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials Perspectives in the treatment of pancreatic adenocarcinoma Novel adjuvant therapies for pancreatic adenocarcinoma Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies Vaccines for pancreatic cancer Current advances in immunotherapy for pancreatic cancer Allogeneic tumor cell vaccines: the promise and limitations in clinical trials Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer Therapeutic cancer vaccines: past, present, and future CD40 immunotherapy for pancreatic cancer The pancreas cancer microenvironment A current perspective on stereotactic body radiation therapy for pancreatic cancer The interplay of immunotherapy and chemotherapy: harnessing potential synergies Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer Re-adapting T cells for cancer therapy: from mouse models to clinical trials.Recent treatment advances and novel therapies in pancreas cancer: a review.Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations.Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation Intraperitoneal administration of a tumor-associated antigen SART3, CD40L, and GM-CSF gene-loaded polyplex micelle elicits a vaccine effect in mouse tumor models Current and future systemic treatment options in metastatic pancreatic cancer.CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.Gene therapy in pancreatic cancer.Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy.A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival Dendritic-cell-based therapeutic cancer vaccines Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor.A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.

P2860

Q24626346-135B5372-78ED-4C6C-90AC-534FEAA016EC Q26749451-E6B64AC6-E170-4E33-BAD8-91208F7DA967 Q26751709-83611BE1-9A59-4DB5-8752-98AC354DC74D Q26765123-A0610744-0B5A-427A-AEDE-5913933324BF Q26766065-0DCDA835-F618-48A1-94AF-AB93FB092C37 Q26774641-FF85983F-7714-4E6D-A474-2B8600D4217C Q26778793-8E516C00-78FC-4E61-8978-4C530FD76BE8 Q26781538-BA424B70-AE30-46B0-B3FB-A3F4732DFE5E Q26797248-36B7268D-10EC-4147-96F7-8423E1D4D60D Q26799425-0D380F17-910D-4B06-8016-8AD7AF19F359 Q26799714-557F6166-040B-427F-8115-2243F764E090 Q26825850-F0AC6698-4745-4786-8DD0-61EA8F0A3DA0 Q26830170-8245B709-9837-45C1-B23B-53FCC7BD40DD Q26852333-816785A7-AE41-41C0-B409-8F2F5637BD82 Q26853171-96DAC39D-7800-49EE-8966-EBAA1E3DA3DC Q26863283-42526964-AD99-4C9A-AA90-603756DCF1B6 Q27012550-AA11901A-A6A2-4F95-9246-983E024A37A3 Q27026705-DBE6726F-19A8-4982-BFFF-6A7600DA3911 Q28077111-8E8EF8D0-03F4-45CC-9364-FC1D41C200DA Q28081893-A6CC91FF-A24C-4625-A55A-1CC6181C931E Q28740545-ECC16C0D-3829-4368-8FDC-BA226683DAD7 Q33588711-356F3863-F420-406E-BCF3-6FEDDDC6DEEC Q33625168-D7FDCEB2-B08A-4D70-B996-BA775BF1C894 Q33728672-09EBB4C3-2CC1-4582-9428-1962D02E1ADB Q33779875-3734E0B8-064B-4CBA-AF69-E72F4FE5714A Q33820788-FF6EBBEC-5A38-4540-A577-BF04171A23DE Q33848077-6B710A7B-7AAC-4EAB-A470-C06927638A8E Q33889445-B1CF2057-E88A-4B1F-98AF-A32D47DF29E4 Q33948033-65B3353D-5C9F-47E8-B0E8-FA59390D8EE7 Q34279134-D75C43D9-ECFD-4178-9C1C-447B7F412971 Q34302954-087A0F84-D620-43ED-B7A9-93C194CE8845 Q34312466-BEC84368-D3AA-4BF0-A3B2-E67973BCDE7F Q34315863-42668202-7673-450D-BA46-441D9D2DEFC9 Q34353251-B4DCC258-6E63-4504-ADFA-F8011314B869 Q34360094-FD88365E-0044-454B-915F-9934B67D8835 Q34362516-907923F6-A620-4FC3-BEC0-B26650349EDD Q34387000-2B3D8EA1-34C2-4D66-9FEB-00D4FD07F1F6 Q34412289-CF95DBC9-8417-4C75-BCBE-DE7F03B6777B Q34644359-DC58FDAC-B878-4551-B225-3227C841CBCF Q34980976-0658F554-0C98-47F0-AB8C-8228DC27FEA7

P2860

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation

http://www.wikidata.org/entity/Q34904065

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A lethally irradiated allogene ...... fficacy, and immune activation

@ast

A lethally irradiated allogene ...... fficacy, and immune activation

@en

A lethally irradiated allogene ...... fficacy, and immune activation

@nl

type

label

A lethally irradiated allogene ...... fficacy, and immune activation

@ast

A lethally irradiated allogene ...... fficacy, and immune activation

@en

A lethally irradiated allogene ...... fficacy, and immune activation

@nl

prefLabel

A lethally irradiated allogene ...... fficacy, and immune activation

@ast

A lethally irradiated allogene ...... fficacy, and immune activation

@en

A lethally irradiated allogene ...... fficacy, and immune activation

@nl

P1433

Q34904065-625A24A5-9CA1-40A3-829D-36E7B2BFFDB1

P1476

Q34904065-58AF132D-7582-4320-9097-BEDC30E7E892

P2093

Q34904065-01131E25-CF8C-4409-AC31-B78D3E38F345

Q34904065-23C94654-60EB-4FDE-B023-0089E5A13872

Q34904065-256BF894-4320-446F-AE10-0512C5819AC4

Q34904065-2A9D5F31-3364-40E1-B72F-7FA923953C7A

Q34904065-426B6F33-C24D-4E63-9E1B-75E24AFAC801

Q34904065-46FB2EDE-1961-467B-8BAC-E5550BD28F0C

Q34904065-5BC6812F-241F-4B6C-B355-F14779B1F5D6

Q34904065-60C1A1E6-0460-4B80-890C-0BB7D3A7E2ED

Q34904065-71C7CEB4-9ED0-469D-AABA-C79147B7976B

Q34904065-85995329-F12A-4FB6-8B26-BC1BFEEBBCFA

P2860

Q34904065-0367BB8B-500B-484A-8A57-BED241647AF1

Q34904065-0CFED6C3-4AD3-421F-BA0E-CC84DA4E3E0A

Q34904065-12F7B143-135D-4872-AC0B-71C4889DDC37

Q34904065-2ACC850B-1F4D-48BA-AD96-B18127784405

Q34904065-3B776BDD-010A-468C-B061-3F7B484754F2

Q34904065-476D2283-8ABB-48AC-BFB6-EB3534C2E851

Q34904065-4D9F5F58-81F3-4F1C-8BB1-ACA82C40E4DE

Q34904065-595B11AE-26EF-4550-BEBF-BB88B6D0A160

Q34904065-9481069F-FC79-4508-84A9-2BE1F8801A56

Q34904065-971B1E97-C238-4487-80C3-59BA7167F7D9

P304

Q34904065-F255D193-0A5C-4F8A-9CBA-CAFFC3C48C2C

P31

Q34904065-6480288D-4CF4-401F-AE06-B8762C030F98

P356

Q34904065-851836D0-4306-4577-8C2F-FD623F412297

P407

Q34904065-E436676A-CEDE-4420-AD0D-B5760AAE06D5

P433

Q34904065-552B9A46-F015-4731-B0A8-A8EA95B4BAFF

P478

Q34904065-CB56B891-65CB-4C7F-8191-737903D4A50D

P50

Q34904065-2AB3C1BF-A1E2-48B2-A6BD-F9847E67D963

Q34904065-A9AC70DB-3B52-49D6-911C-7746A702A190

Q34904065-C3528024-207D-4D39-9C7C-F38212D2AFE0

Q34904065-F829C75E-780D-452E-B08F-FAAB2624CD76

P577

Q34904065-F68973B8-7EF9-4C6C-9FCB-B0AF7BA243E9

P698

Q34904065-5DF3395B-CF98-47AB-A53D-B72F16DE29C2

P921

Q34904065-3332793D-4009-406F-9A43-FD9C92209D5E

Q34904065-D1D13190-8F5A-4B13-A06C-735D4FBE0C5D

Q34904065-D694AB7D-A433-434B-BED1-D0DA12F2E87D

P932

Q34904065-51B592E6-C4D4-4B9B-A706-8DFC9D35953B

P356

SLA.0B013E3181FD271C

P1433

Annals of Surgery

P1476

A lethally irradiated allogene ...... fficacy, and immune activation

@en

P2093

Barbara Biedrzycki

http://www.w3.org/2001/XMLSchema#string

Barry Kobrin

http://www.w3.org/2001/XMLSchema#string

Beth Onners

http://www.w3.org/2001/XMLSchema#string

Charles J Yeo

http://www.w3.org/2001/XMLSchema#string

Dan Laheru

http://www.w3.org/2001/XMLSchema#string

Dung Le

http://www.w3.org/2001/XMLSchema#string

Elizabeth Sugar

http://www.w3.org/2001/XMLSchema#string

Eric Lutz

http://www.w3.org/2001/XMLSchema#string

Irena Tartakovsky

http://www.w3.org/2001/XMLSchema#string

John L Cameron

http://www.w3.org/2001/XMLSchema#string

P2860

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

Cancer statistics, 2008

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients

Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.

P304

328-335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/SLA.0B013E3181FD271C

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

253

http://www.w3.org/2001/XMLSchema#string

P50

Ralph H. Hruban

Elizabeth Jaffee

Rajni B. Sharma

Steven T Piantadosi

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21217520

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3085934

http://www.w3.org/2001/XMLSchema#string